Touchefeu Y, et al. - In a randomized phase 3 study with predefined second-line therapy (L2), researchers determined prognostic factors in patients treated with L2 for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma. To compare the characteristics of patients treated in L2 with those of patients who did not receive L2, Chi square tests were used. Using a Cox model, prognostic factors in L2 for progression-free survival and overall survival (OS) were analyzed. The only favorable prognostic factors for OS were age ≥ 60 years at diagnosis and ECOG score 0/1 before L2.